Search Results
Oct 30, 2025, 16:15 ET NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
Reorganization, as amended from time to time, dated as of November 4, 2024 (the "Merger Agreement"), by and among NewcelX (f/k/a NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS")), NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. ("Kadimastem"), effective as of October 30, 2025 (the "Merger"). Upon
More news about: NewCelX Ltd.; NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 30, 2025, 07:00 ET NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
model: About NLS Pharmaceutics Ltd. NLS Pharmaceutics (Nasdaq: NLSP) is a Swiss biopharmaceutical company developing therapies for CNS and neurodegenerative disorders. Following its merger with Kadimastem Ltd., NLS will
More news about: NLS Pharmaceutics Ltd.
Oct 29, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders,
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 29, 2025, 06:00 ET NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 29, 2025, 03:53 ET NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd.
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 27, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 23, 2025, 06:01 ET NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Sep 30, 2025, 07:00 ET NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Sept. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Sep 10, 2025, 06:00 ET Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
therapies for patients suffering from some of the most challenging diseases." About NLS PharmaceuticsNLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a Swiss-based biopharmaceutical company focused on the development of innovative therapies for central nervous system disorders and related indications.
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.